Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Net Cash Flow (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Net Cash Flow for 16 consecutive years, with -$542000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Net Cash Flow fell 458.94% to -$542000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $1.7 million, a 312.45% increase, with the full-year FY2024 number at -$35000.0, down 136.84% from a year prior.
  • Net Cash Flow was -$542000.0 for Q3 2025 at Harvard Bioscience, down from $1.3 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $2.4 million in Q4 2021 to a low of -$2.4 million in Q1 2021.
  • A 5-year average of -$91000.0 and a median of -$98000.0 in 2024 define the central range for Net Cash Flow.
  • Peak YoY movement for Net Cash Flow: tumbled 916.25% in 2021, then skyrocketed 793.5% in 2025.
  • Harvard Bioscience's Net Cash Flow stood at $2.4 million in 2021, then plummeted by 112.15% to -$286000.0 in 2022, then plummeted by 205.59% to -$874000.0 in 2023, then skyrocketed by 88.79% to -$98000.0 in 2024, then plummeted by 453.06% to -$542000.0 in 2025.
  • Per Business Quant, the three most recent readings for HBIO's Net Cash Flow are -$542000.0 (Q3 2025), $1.3 million (Q2 2025), and $1.1 million (Q1 2025).